-
Something wrong with this record ?
Analysis of serum concentrations of metoprolol and its metabolite α-hydroxymetoprolol in patients with heart failure with reduced ejection fraction: a pilot study in routine health care
I. Kacirova, M. Lazarova, R. Urinovska, J. Dodulik, J. Vaclavik
Language English Country England, Great Britain
Document type Journal Article
- MeSH
- Adrenergic beta-1 Receptor Antagonists * administration & dosage MeSH
- Cytochrome P-450 CYP2D6 metabolism MeSH
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Metoprolol * administration & dosage pharmacokinetics analogs & derivatives pharmacology MeSH
- Natriuretic Peptide, Brain * blood MeSH
- Peptide Fragments blood MeSH
- Pilot Projects MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Heart Failure * drug therapy physiopathology MeSH
- Stroke Volume * drug effects MeSH
- Dose-Response Relationship, Drug * MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
BACKGROUND: The cardioselective β-1 receptor antagonist metoprolol is used to treat heart failure. It is metabolized in the liver, primarily by cytochrome 2D6. RESEARCH DESIGN AND METHODS: In this study, trough serum concentrations of metoprolol and its metabolite α-hydroxymetoprolol were measured in patients with heart failure with reduced ejection fraction. RESULTS: Concentrations were 1.3-122.9 μg/L for metoprolol and 1.3-125.7 μg/L for α-hydroxymetoprolol, metabolic ratios were 0.11-98.32. The median weight-adjusted apparent clearance of metoprolol was 53.07 (range 3.24-500.0). Metoprolol and α-hydroxymetoprolol concentrations correlated with both daily dose and dose per kilogram of body weight. However, metoprolol concentrations at the same daily dose showed a wide variability. Patients taking 100 mg/day had significantly lower NT-proBNP values than those taking 25 or 50 mg/day. Patients with LVEF ≤ 35% versus > 35% used significantly lower daily doses and doses per kilogram of body weight, although metoprolol concentrations did not differ. A poor cytochrome 2D6 metabolizer phenotype was detected in two patients. CONCLUSIONS: Metoprolol concentrations showed a wide interindividual variability at the same daily dose. Simultaneous determination of metoprolol and α-hydroxymetoprolol concentrations could identify patients at risk of possible accumulation of metoprolol leading to intoxication or, conversely, patients at risk of underdosing. [Figure: see text].
Department of Clinical Pharmacology Faculty of Medicine University of Ostrava Ostrava Czech Republic
Department of Internal Medicine and Cardiology University Hospital Ostrava Ostrava Czech Republic
Department of Internal Medicine Faculty of Medicine University of Ostrava Ostrava Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25010415
- 003
- CZ-PrNML
- 005
- 20250429135156.0
- 007
- ta
- 008
- 250415s2025 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1080/17512433.2025.2450257 $2 doi
- 035 __
- $a (PubMed)39757778
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Kacirova, Ivana $u Department of Clinical Pharmacology, Institute of Laboratory Medicine, University Hospital Ostrava, Ostrava, Czech Republic $u Department of Clinical Pharmacology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
- 245 10
- $a Analysis of serum concentrations of metoprolol and its metabolite α-hydroxymetoprolol in patients with heart failure with reduced ejection fraction: a pilot study in routine health care / $c I. Kacirova, M. Lazarova, R. Urinovska, J. Dodulik, J. Vaclavik
- 520 9_
- $a BACKGROUND: The cardioselective β-1 receptor antagonist metoprolol is used to treat heart failure. It is metabolized in the liver, primarily by cytochrome 2D6. RESEARCH DESIGN AND METHODS: In this study, trough serum concentrations of metoprolol and its metabolite α-hydroxymetoprolol were measured in patients with heart failure with reduced ejection fraction. RESULTS: Concentrations were 1.3-122.9 μg/L for metoprolol and 1.3-125.7 μg/L for α-hydroxymetoprolol, metabolic ratios were 0.11-98.32. The median weight-adjusted apparent clearance of metoprolol was 53.07 (range 3.24-500.0). Metoprolol and α-hydroxymetoprolol concentrations correlated with both daily dose and dose per kilogram of body weight. However, metoprolol concentrations at the same daily dose showed a wide variability. Patients taking 100 mg/day had significantly lower NT-proBNP values than those taking 25 or 50 mg/day. Patients with LVEF ≤ 35% versus > 35% used significantly lower daily doses and doses per kilogram of body weight, although metoprolol concentrations did not differ. A poor cytochrome 2D6 metabolizer phenotype was detected in two patients. CONCLUSIONS: Metoprolol concentrations showed a wide interindividual variability at the same daily dose. Simultaneous determination of metoprolol and α-hydroxymetoprolol concentrations could identify patients at risk of possible accumulation of metoprolol leading to intoxication or, conversely, patients at risk of underdosing. [Figure: see text].
- 650 12
- $a metoprolol $x aplikace a dávkování $x farmakokinetika $x analogy a deriváty $x farmakologie $7 D008790
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a pilotní projekty $7 D010865
- 650 12
- $a srdeční selhání $x farmakoterapie $x patofyziologie $7 D006333
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a tepový objem $x účinky léků $7 D013318
- 650 12
- $a antagonisté beta-1-adrenergních receptorů $x aplikace a dávkování $7 D058671
- 650 12
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 12
- $a natriuretický peptid typu B $x krev $7 D020097
- 650 _2
- $a peptidové fragmenty $x krev $7 D010446
- 650 _2
- $a cytochrom P-450 CYP2D6 $x metabolismus $7 D019389
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a dospělí $7 D000328
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Lazarova, Marie $u Department of Internal Medicine and Cardiology, University Hospital Ostrava, Ostrava, Czech Republic $u Department of Internal Medicine, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
- 700 1_
- $a Urinovska, Romana $u Department of Clinical Pharmacology, Institute of Laboratory Medicine, University Hospital Ostrava, Ostrava, Czech Republic
- 700 1_
- $a Dodulik, Jozef $u Department of Internal Medicine and Cardiology, University Hospital Ostrava, Ostrava, Czech Republic $u Department of Internal Medicine, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
- 700 1_
- $a Vaclavik, Jan $u Department of Internal Medicine and Cardiology, University Hospital Ostrava, Ostrava, Czech Republic $u Department of Internal Medicine, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
- 773 0_
- $w MED00174410 $t Expert review of clinical pharmacology $x 1751-2441 $g Roč. 18, č. 1-2 (2025), s. 89-99
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39757778 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250415 $b ABA008
- 991 __
- $a 20250429135152 $b ABA008
- 999 __
- $a ok $b bmc $g 2311645 $s 1247496
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 18 $c 1-2 $d 89-99 $e 20250116 $i 1751-2441 $m Expert review of clinical pharmacology $n Expert Rev Clin Pharmacol $x MED00174410
- LZP __
- $a Pubmed-20250415
